Truist lowered the firm’s price target on Harmony Biosciences (HRMY) to $45 from $48 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences partners with Beacon Biosignals for EEG in hypersomnia
- Harmony Biosciences presents ARGUS trial data at American Epilepsy Society
- Buy Rating Affirmed for Harmony Biosciences: Promising EPX-100 Data Boosts Confidence
- Harmony Biosciences price target raised to $46 from $39 at Mizuho
- Positive Outlook on Harmony Biosciences Holdings: Promising Pipeline Developments and Revenue Growth Potential